Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia

Xiao-Wen Zhan, Liping Deng, Zhiyuan Wang, Ju Zhang, Mengzhu Wang, Shujun Li2022 · DOI

TL;DR

This study investigates why some children with Mycoplasma pneumoniae pneumonia (MPP) fail to respond to standard macrolide antibiotics, a condition known as Refractory MPP (RMPP). While drug-resistance mutations in the 23S rRNA gene are highly prevalent and lead to more severe clinical symptoms and longer hospital stays, the researchers found that these mutations alone do not statistically predict whether a case will become "refractory," suggesting that RMPP is a complex, multifactorial condition involving the host's immune response.

What Problem Does This Paper Address?

Mycoplasma pneumoniae (MP) is a leading cause of community-acquired pneumonia in children. For decades, macrolide antibiotics (like Azithromycin) have been the first-line treatment. However, resistance is skyrocketing, particularly in East Asia, leading to an increase in RMPP—cases where clinical symptoms and lung imaging worsen despite seven days of proper antibiotic therapy.

The mechanism of resistance is primarily linked to point mutations in the V region of the 23S rRNA gene (specifically at positions A2063G and A2064G), which prevent the antibiotic from binding to the bacterial ribosome. This paper seeks to determine if these specific genetic mutations in the bacteria are the primary drivers of RMPP or if other clinical factors are at play.

Methods

The researchers conducted a retrospective study of 48 children hospitalized with MPP between 2019 and 2021.

  • Sampling: Unlike many studies that rely on throat swabs, this team used bronchoalveolar lavage fluid (BALF) collected via fiberoptic bronchoscopy. BALF provides a more accurate representation of the microbial environment deep within the lungs.
  • Molecular Analysis: They used Fluorescent Quantitative PCR (FQ-PCR) to measure MP-DNA loads and identify A2063G/A2064G mutations.
  • Grouping: Patients were categorized twice: once by clinical status (RMPP vs. non-RMPP) and once by genetic status (Mutated vs. Non-mutated).
  • Statistical Analysis: They employed multivariate logistic regression to isolate which factors—ranging from inflammatory markers like C-reactive protein (CRP) to bacterial DNA load—actually correlated with the refractory nature of the disease.

Datasets

The study utilized a clinical dataset of 48 pediatric patients from the First Affiliated Hospital of Xinxiang Medical College, China. Data points included:

  • Demographics (age, sex).
  • Laboratory markers (WBC count, CRP, procalcitonin, LDH).
  • Imaging (CT scans showing unilobar vs. multilobar consolidation).
  • Bronchoscopic findings (mucosal congestion, sputum emboli, plastic bronchi).
  • Treatment timelines (fever duration, hospitalization length).

Key Insights and Ideas

  • High Resistance Prevalence: A staggering 64.6% of the children carried the drug-resistance mutation. This highlights the severity of the antibiotic resistance crisis in pediatric respiratory infections.
  • Resistance $\neq$ Refractory: The most surprising finding was that while the drug-resistance mutation was common in the RMPP group (74.2%), it was also present in nearly half (47.1%) of the non-RMPP group. Statistical analysis showed that the mutation itself was not significantly correlated with the occurrence of RMPP ($P = 0.065$).
  • The "Combination of Factors" Hypothesis: The authors argue that RMPP isn't just about the bacteria's ability to survive antibiotics. It is likely driven by a "perfect storm" of high bacterial loads, intense host inflammatory responses (evidenced by high CRP), and potential immune dysfunction.
  • Visualizing Severity: Bronchoscopy revealed that children with the mutation had significantly more "sputum emboli" (plugs of mucus and debris) than those without, explaining why these children often require invasive procedures to clear their airways.

Key Results

  • Clinical Impact of Mutations: Children in the mutated group had significantly higher MP-DNA loads, higher CRP levels, and longer fever durations (12.68 vs. 9.12 days) compared to the non-mutated group.
  • Hospitalization: The RMPP group stayed in the hospital nearly twice as long as the non-RMPP group (17.16 vs. 9.12 days).
  • Imaging: Multilobar involvement (pneumonia in multiple sections of the lung) was significantly more common in RMPP cases (21/31) than in non-RMPP cases (4/17).
  • Regression Analysis: When looking at all variables, the duration of macrolide use was a significant predictor of RMPP, but the presence of the A2063G/A2064G mutation was not an independent predictor.

Limitations and Future Work

  • Sample Size: The study is limited by a small cohort (n=48), which may affect the statistical power of the regression analysis.
  • Genetic Scope: The researchers only tested for the two most common point mutations. Other rare mutations or different resistance mechanisms (like active efflux pumps) were not explored.
  • Immune Profiling: While the authors suggest that the host immune response is a key factor in RMPP, they did not perform deep immunologic profiling (e.g., cytokine panels) to confirm this.
  • Future Direction: The authors suggest that early monitoring of inflammatory markers and bacterial loads—rather than just genetic testing—may be the best way to predict and intervene in RMPP cases.

Summary updated

Abstract

The mutation rate of drug-resistance genes in children with MPP is high, the inflammatory index and MP-DNA load are high, the course of the disease is long, and the changes under bronchoscopy are severe. The occurrence of RMPP is not only determined by drug-resistance genes but may also be the result of a combination of factors.
BibTeX
@inproceedings{zhan2022correlation,
  author = {Xiao-Wen Zhan and Liping Deng and Zhiyuan Wang and Ju Zhang and Mengzhu Wang and Shujun Li},
  title = {{Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia}},
  booktitle = {˜The},
  year = {2022},
  doi = {10.1186/s13052-022-01376-6},
}
Figure